X

Trial Profile

A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 15 Jul 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axicabtagene ciloleucel (Primary) ; Utomilumab (Primary) ; Cyclophosphamide; Fludarabine
Indications B-cell lymphoma; Diffuse large B cell lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms ZUMA-11
Sponsors Kite Pharma

Most Recent Events

21 Dec 2022 Status changed from active, no longer recruiting to discontinued.
06 Dec 2022 Planned End Date changed from 1 Sep 2022 to 1 Dec 2022.
11 May 2022 Planned End Date changed from 1 Jun 2022 to 1 Sep 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com